GKB Ophthalmics Ltd (533212)
சுருக்கம்
The board meets on 12 Nov 2026 to consider the Q2 FY27 results.
நிகழ்வுகள்
- அடுத்த முடிவுகள்
- 12 நவ. 2026 (Q2 FY27)
- சமீபத்திய முடிவுகள்
- Q1 FY27, தாக்கல் செய்யப்பட்டது 13 ஆக. 2026
- இயக்குநர் குழுக் கூட்ட அறிவிப்பு
- 12 ஆக. 2026
பங்குச் சந்தைத் தரவு. ஒவ்வொரு எண்ணும் அதன் சொந்தப் பக்கம் காட்டும் வடிவத்திலேயே; தேதிகள் தரவின் தேதிகள். தகவலுக்கு மட்டுமே, முதலீட்டு ஆலோசனை அல்ல.
📈 பங்கு விலை & நிகழ்வுகள்
Q2 FY27 முடிவுகள்
📅 அடுத்த நிதி முடிவுகள்: 12 நவ. 2026 (இயக்குநர் குழுக் கூட்டம்)GKB Ophthalmics Ltd-இன் இயக்குநர் குழுக் கூட்டம் 12 நவ. 2026 அன்று நடைபெறுகிறது; அதில் அதன் Q2 FY27 முடிவுகள் பரிசீலிக்கப்படும் (ஜூலை-செப்டம்பர் 2026).
In its latest reported quarter, Q1 FY27, GKB Ophthalmics' revenue was ₹33.0 Cr (+2.3% year on year, +10.9% on the previous quarter), and net profit ₹1.8 Cr (against a loss a year earlier); the operating margin was 8.2%.
| Q1 FY27 (₹ கோடி) | மதிப்பு | YoY Q1 FY26-உடன் | QoQ |
|---|---|---|---|
| வருவாய் | ₹33.0 | +2.3% | +10.9% |
| செயல்பாட்டு லாபம் | ₹2.7 | +238.3% | -12.1% |
| நிகர லாபம் | ₹1.8 | நஷ்டத்திலிருந்து | +64.9% |
| EPS (₹) | 2.00 | நஷ்டத்திலிருந்து | +426.3% |
| செயல்பாட்டு லாப வரம்பு | 8.2% | — | — |
📢 சமீபத்திய கார்ப்பரேட் அறிவிப்புகள்
GKB Ophthalmics reported standalone revenue from operations of ₹6.79 Cr for Q2 FY27, up 11.2% YoY compared to ₹6.11 Cr in Q2 FY26. Standalone net loss widened significantly to ₹1.16 Cr from a loss of ₹0.52 Cr in the year-ago period and a loss of ₹0.48 Cr in Q1 FY27. Total expenses rose to ₹7.98 Cr, outpacing total income of ₹6.82 Cr, leading to a basic EPS of -₹2.30. Operating cash flow for H1 FY27 turned negative at -₹1.35 Cr, compared to positive ₹0.35 Cr in H1 FY26.
- Standalone revenue from operations stood at ₹679.23 Lakhs in Q2 FY27 vs ₹610.64 Lakhs in Q2 FY26
- Net loss for Q2 FY27 expanded to ₹115.91 Lakhs vs ₹52.26 Lakhs in Q2 FY26
- Total expenses stood at ₹797.64 Lakhs against total income of ₹681.73 Lakhs
- Net cash used in operating activities stood at -₹134.99 Lakhs for H1 FY27 vs cash generated of ₹34.63 Lakhs in H1 FY26
- Step-down subsidiary Prime Ophthalmics Products PTY Limited closed on July 02, 2026, leading to a write-off of ₹43.50 Lakhs in Q1
GKB Ophthalmics reported a 26.5% YoY decline in standalone revenue to ₹6.40 Cr for Q1 FY27. However, the standalone net loss narrowed significantly to ₹0.50 Cr from a loss of ₹2.14 Cr in the same quarter last year, aided by a reduction in total expenses from ₹10.97 Cr to ₹7.61 Cr. A key development is the receipt of ₹11.70 Cr from the voluntary winding up of its subsidiary GSV Ophthalmics, which represents approximately 15.6% of the company's current market capitalization. The company also completed the closure of its step-down subsidiary, Prime Ophthalmics Products PTY Ltd, resulting in a ₹43.50 lakh write-off.
- Standalone revenue for Q1 FY27 stood at ₹6.40 Cr, down from ₹8.71 Cr in Q1 FY26.
- Standalone net loss narrowed to ₹0.50 Cr compared to a loss of ₹2.14 Cr in the previous year's quarter.
- Received ₹11.70 Cr cash inflow from the voluntary winding up of material subsidiary GSV Ophthalmics.
- Wrote off ₹43.50 lakhs following the closure of step-down subsidiary Prime Ophthalmics Products PTY Ltd on July 02, 2026.
- Total standalone expenses decreased by 30.6% YoY to ₹7.61 Cr.
GKB Ophthalmics reported a standalone revenue of ₹6.40 Cr for Q1 FY27, a 27.6% decline from ₹8.84 Cr in the same quarter last year. The company is currently contesting a significant legal demand of ₹8.82 Cr from the Labour Commissioner, which represents approximately 16.6% of its net worth (₹53 Cr). Additionally, the company has closed its non-performing Australian step-down subsidiary, writing off an investment of AED 1,69,325.58. While standalone net losses narrowed to ₹0.67 Cr from ₹1.88 Cr YoY, the legal dispute remains a primary concern for liquidity.
- Standalone revenue for Q1 FY27 decreased to ₹6.40 Cr from ₹8.84 Cr in Q1 FY26.
- Legal demand of ₹8.82 Cr from the Mamlatdar of Bardez Taluka challenged in High Court (Hearing: Aug 19, 2026).
- Write-off of AED 1,69,325.58 following the closure of Prime Ophthalmics Products PTY Limited on July 02, 2026.
- Standalone net loss narrowed to ₹0.67 Cr for the quarter ended June 30, 2026, compared to ₹1.88 Cr loss YoY.
- Prescription Optical Products LLC (POPL) restructured into a Wholly Owned Subsidiary of the Sharjah-based FZE unit.
GKB Ophthalmics has scheduled its 44th Annual General Meeting (AGM) for August 28, 2026, to review the performance of FY 2025-26. The company has dispatched letters to shareholders without registered email addresses, providing a direct web-link to the Annual Report. This follows a turnaround year where the company reported a Net Profit of ₹3.0 cr in FY26, recovering from a ₹7.0 cr loss in FY25. The filing also serves as a regulatory reminder for shareholders to update KYC details and dematerialize physical shares to ensure receipt of future payments.
- 44th Annual General Meeting scheduled for August 28, 2026, at 11:00 AM in Goa.
- Cut-off date for identifying shareholders for this communication was July 24, 2026.
- Company reported a recovery in FY26 with Revenue of ₹149 cr and Net Profit of ₹3.0 cr.
- Mandatory KYC updates required for physical shareholders to receive dividends/payments after April 1, 2024.
- Promoter holding remains stable at 51.15% as of June 2026.
GKB Ophthalmics has announced its 44th Annual General Meeting (AGM) will be held on August 25, 2026. The register of members and share transfer books will remain closed from August 19 to August 25, 2026, for this purpose. The company explicitly stated that no dividend has been proposed for the financial year 2025-26. This follows a year where the company returned to profitability with a PAT of ₹3 Cr compared to a ₹7 Cr loss in FY25.
- 44th Annual General Meeting scheduled for August 25, 2026
- Book closure period defined as August 19, 2026, to August 25, 2026
- Zero dividend proposed for the financial year 2025-26
- Company reported a turnaround to ₹3 Cr profit in FY26 from a ₹7 Cr loss in FY25
GKB Ophthalmics has released its FY26 Annual Report, confirming a turnaround to a consolidated profit of ₹1.22 Cr from a loss of ₹7.04 Cr in FY25. Revenue grew significantly to ₹149 Cr in FY26, up from ₹109 Cr in the previous year. The company has scheduled its 44th AGM for August 25, 2026, to approve these results and re-appoint key management. Proposed re-appointments include CMD K.G. Gupta for a 3-year term starting April 2027 and Executive Director Cedric Lobo for 2 years.
- Achieved consolidated net profit of ₹1.22 Cr in FY26 compared to a ₹7.04 Cr loss in FY25
- Annual revenue increased by 36.7% to ₹149 Cr in FY26 from ₹109 Cr in FY25
- Proposed re-appointment of CMD K.G. Gupta with a basic salary of ₹3.60 lakhs per month plus 1% commission on net profits
- Proposed re-appointment of Executive Director Cedric Lobo with a remuneration range of ₹9.50 lakhs to ₹15.00 lakhs p.a.
- 44th Annual General Meeting scheduled for August 25, 2026, at the company's registered office in Goa
GKB Ophthalmics has scheduled a board meeting for August 12, 2026, to approve its standalone and consolidated financial results for the quarter ended June 30, 2026. The company is coming off a recovery phase, with TTM PAT at Rs 3 Cr compared to a full-year loss of Rs 7.0 Cr in FY25. Investors will be monitoring if the company can improve upon the Rs 0.64 Cr loss reported in the same quarter last year (June 2025). The trading window for designated persons has been closed since July 01, 2026.
- Board meeting scheduled for August 12, 2026, to approve Q1 FY27 results
- Trading window for equity shares closed from July 01, 2026
- Company reported TTM revenue of Rs 149 Cr against a market cap of Rs 69 Cr
- Previous year's corresponding quarter (Jun 2025) saw a net loss of Rs 0.64 Cr
GKB Ophthalmics has received a formal 'Notice of Demand' for ₹8.82 crore from the Mamlatdar of Bardez Taluka, Goa, following a long-standing labour dispute (Case No. 32/09). The notice, received on July 13, 2026, mandates the recovery of dues within a strict 10-day period. This stems from an Industrial Tribunal award dated May 25, 2021, and a subsequent recovery order by the Labour Commissioner in September 2025. The company intends to challenge this demand by filing a writ petition in the High Court of Bombay.
- Demand notice for ₹8,82,00,856 received on July 13, 2026, at 5:00 PM.
- Payment or recovery of the full amount is required within a 10-day window.
- The dispute originates from an Industrial Tribunal Award passed on May 25, 2021.
- The Labour Commissioner had previously passed the recovery order on September 4, 2025.
- Company is seeking legal relief via a writ petition in the High Court of Bombay.
நிறுவனச் சுயவிவரம்
நிதிச் செயல்திறன்
இந்த நிறுவனத்துக்கான நிதிப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
செயல்பாட்டு உந்துசக்திகள்
இந்த நிறுவனத்திற்கான செயல்பாட்டுப் பகுப்பாய்வுத் தரவு இன்னும் கிடைக்கவில்லை.
வியூக வளர்ச்சி
இந்த நிறுவனத்துக்கான வியூக வளர்ச்சிப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
வெளிப்புறக் காரணிகள்
இந்த நிறுவனத்துக்கு வெளிப்புறக் காரணிகளின் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
ஒழுங்குமுறை & நிர்வாகம்
இந்த நிறுவனத்திற்கான ஒழுங்குமுறைப் பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
அபாயப் பகுப்பாய்வு
இந்நிறுவனத்துக்கான அபாய பகுப்பாய்வு இன்னும் கிடைக்கவில்லை.
